TY - T1的治疗药物监测上一页ent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00173-2017 VL - 49 IS - 4 SP - 1700173 AU - Davies Forsman, Lina AU - Bruchfeld, Judith AU - Alffenaar, Jan-Willem C. Y1 - 2017/04/01 UR - //www.qdcxjkg.com/content/49/4/1700173.abstract N2 - The new short-course World Health Organization (WHO)-endorsed regimen for multidrug-resistant (MDR) tuberculosis (TB) resistant to rifampicin and isoniazid gives hope for patients and care-givers. However, there is still an unacceptable proportion of treatment failure and evidence of man-made acquired drug resistance of fluoroquinolones during programmatic treatment of MDR-TB [1]. The appropriate use of fluoroquinolones is crucial in MDR-TB treatment, perhaps even more so in the new WHO-endorsed short-course MDR-TB regimen. Current shortcomings with inappropriate use of fluoroquinolones, such as underdosing, need to be avoided in order to prevent failure of the new short-course regimen.Therapeutic drug monitoring of fluoroquinolones might prevent acquired XDR-TB http://ow.ly/jj6b309QXyZ ER -